-
-
-
-
-
-
-
Xilio Therapeutics (XLO) Announces Pricing of $50.0 Million Public Offering
-
-
-
-
-
-
-
Xilio Therapeutics (XLO) Reports Initial Trial Data from Phase 1C Dose Escalation for Vilastobart
-
-
-
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

